These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 19573982

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The activity of aminoacyl-tRNA synthetase-interacting multi-functional protein 1 (AIMP1) on endothelial cells is mediated by the assembly of a cytoskeletal protein complex.
    Jackson VC, Dewilde S, Albo AG, Lis K, Corpillo D, Canepa B.
    J Cell Biochem; 2011 Jul; 112(7):1857-68. PubMed ID: 21416500
    [Abstract] [Full Text] [Related]

  • 3. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS, Lee BC, Kim E, Cho D, Cohen EP.
    Vaccine; 2008 Nov 05; 26(47):5928-34. PubMed ID: 18793691
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB.
    Bioconjug Chem; 2006 Nov 05; 17(1):179-88. PubMed ID: 16417267
    [Abstract] [Full Text] [Related]

  • 6. Structural separation of different extracellular activities in aminoacyl-tRNA synthetase-interacting multi-functional protein, p43/AIMP1.
    Han JM, Park SG, Lee Y, Kim S.
    Biochem Biophys Res Commun; 2006 Mar 31; 342(1):113-8. PubMed ID: 16472771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Tyroservatide inhibits the growth of human hepatocarcinoma in nude mice].
    Jia J, Lu R, Fu Z, Qiu S, Shi LX, Jian X, Liu JY, Li HQ, Che XC, Yao Z.
    Zhonghua Zhong Liu Za Zhi; 2006 Jun 31; 28(6):426-8. PubMed ID: 17152487
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
    Zhang ZM, Yang XY, Deng SH, Xu W, Gao HQ.
    Chin Med J (Engl); 2007 Aug 05; 120(15):1336-42. PubMed ID: 17711740
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 13. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
    Song Y, Shen K, He CX.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep 15; 42(9):617-22. PubMed ID: 17983518
    [Abstract] [Full Text] [Related]

  • 14. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF, Belvin M, Boggs J, Deng Y, Hoeflich KP, Ly J, Merchant M, Orr C, Plise E, Robarge K, Martini JF, Kassees R, Aoyama RG, Ramaiya A, Johnston SH.
    Drug Metab Dispos; 2012 May 15; 40(5):919-27. PubMed ID: 22315332
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.
    Clin Cancer Res; 2005 Apr 15; 11(8):3045-54. PubMed ID: 15837760
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 18. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 19. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan 15; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model.
    Lee YS, Han JM, Kang T, Park YI, Kim HM, Kim S.
    Mol Cells; 2006 Apr 30; 21(2):213-7. PubMed ID: 16682815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.